{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:53:18Z","timestamp":1783119198630,"version":"3.54.6"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010318","name":"University of Manitoba","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010318","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1053\/j.ajkd.2020.03.019","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T11:19:24Z","timestamp":1590405564000},"page":"471-479.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study"],"prefix":"10.1053","volume":"76","author":[{"given":"Christie","family":"Rampersad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyal","family":"Kraut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid H.","family":"Whitlock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Komenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Rigatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navdeep","family":"Tangri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2020.03.019_bib1","unstructured":"International Diabetes Federation. IDF Diabetes Atlas 7th edition. https:\/\/diabetesatlas.org\/en\/, 2015, 26 November 2019."},{"issue":"10027","key":"10.1053\/j.ajkd.2020.03.019_bib2","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(16)00618-8","article-title":"Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants","volume":"387","author":"Zhou","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1053\/j.ajkd.2020.03.019_bib3","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"issue":"9529","key":"10.1053\/j.ajkd.2020.03.019_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(06)68967-8","article-title":"Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study","volume":"368","author":"Booth","year":"2006","journal-title":"Lancet"},{"issue":"9","key":"10.1053\/j.ajkd.2020.03.019_bib5","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"10.1053\/j.ajkd.2020.03.019_bib6","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2020.03.019_bib7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1053\/j.ajkd.2020.03.019_bib8","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1053\/j.ajkd.2020.03.019_bib9","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1016\/j.jacc.2018.03.009","article-title":"Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 Study","volume":"71","author":"Kosiborod","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1053\/j.ajkd.2020.03.019_bib10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2020.03.019_bib11","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/j.jcjd.2017.10.034","article-title":"Pharmacologic glycemic management of type 2 diabetes in adults","volume":"42","author":"Lipscombe","year":"2018","journal-title":"Can J Diabetes"},{"key":"10.1053\/j.ajkd.2020.03.019_bib12","unstructured":"U.S. Food and Drug Association. FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR) | FDA. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-strengthens-kidney-warnings-diabetes-medicines-canagliflozin. Published 2016, 27 November 2019."},{"issue":"12","key":"10.1053\/j.ajkd.2020.03.019_bib13","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.numecd.2017.10.011","article-title":"Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: analysis of the FDA adverse event report system database","volume":"27","author":"Perlman","year":"2017","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"15","key":"10.1053\/j.ajkd.2020.03.019_bib14","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","article-title":"Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function data from the CANVAS program","volume":"138","author":"Neuen","year":"2018","journal-title":"Circulation"},{"issue":"4","key":"10.1053\/j.ajkd.2020.03.019_bib15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1053\/j.ajkd.2020.03.019_bib16","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1681\/ASN.2018010103","article-title":"Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial","volume":"29","author":"Wanner","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2020.03.019_bib17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.socscimed.2007.08.017","article-title":"From health research to social research: privacy, methods, approaches","volume":"66","author":"Roos","year":"2008","journal-title":"Soc Sci Med"},{"issue":"1","key":"10.1053\/j.ajkd.2020.03.019_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0895-4356(98)00126-7","article-title":"A\u00a0research registry: uses, development, and accuracy","volume":"52","author":"Roos","year":"1999","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"3","key":"10.1053\/j.ajkd.2020.03.019_bib19","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1468-0009.2010.00604.x","article-title":"Enhancing policymakers\u2019 understanding of disparities: relevant data from an information-rich environment","volume":"88","author":"Roos","year":"2010","journal-title":"Milbank Q"},{"issue":"3","key":"10.1053\/j.ajkd.2020.03.019_bib20","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/jamia\/ocx078","article-title":"Assessing the quality of administrative data for research: a framework from the Manitoba Centre for Health Policy","volume":"25","author":"Smith","year":"2018","journal-title":"J\u00a0Am Med Inform Assoc"},{"key":"10.1053\/j.ajkd.2020.03.019_bib21","first-page":"S1","article-title":"KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"113","year":"2009","journal-title":"Kidney Int Suppl"},{"issue":"7","key":"10.1053\/j.ajkd.2020.03.019_bib22","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s00101-014-2344-5","article-title":"New KDIGO guidelines on acute kidney injury. practical recommendations D","volume":"63","author":"Zarbock","year":"2014","journal-title":"Anaesthesist"},{"key":"10.1053\/j.ajkd.2020.03.019_bib23","series-title":"Local and Global Optimal Propensity Score Matching","author":"Coca-Perraillon","year":"2007"},{"issue":"11","key":"10.1053\/j.ajkd.2020.03.019_bib24","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2337\/dc17-1011","article-title":"Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis","volume":"40","author":"Nadkarni","year":"2017","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1053\/j.ajkd.2020.03.019_bib25","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/dom.13532","article-title":"Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: real-world data analysis. Diabetes","volume":"21","author":"Cahn","year":"2019","journal-title":"Obes Metab"},{"issue":"6","key":"10.1053\/j.ajkd.2020.03.019_bib26","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1159\/000484633","article-title":"The Canagliflozin and Renal Endpoints in Diabetes With Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics","volume":"46","author":"Jardine","year":"2018","journal-title":"Am J Nephrol"},{"issue":"21","key":"10.1053\/j.ajkd.2020.03.019_bib27","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1056\/NEJMcibr1608564","article-title":"Nephron protection in diabetic\u00a0kidney disease","volume":"375","author":"Anders","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1053\/j.ajkd.2020.03.019_bib28","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/dom.12654","article-title":"Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers","volume":"18","author":"Heerspink","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1053\/j.ajkd.2020.03.019_bib29","first-page":"844","article-title":"Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys","volume":"8","author":"Sano","year":"2016","journal-title":"J\u00a0Clin Med Res"},{"key":"10.1053\/j.ajkd.2020.03.019_bib30","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis","volume":"39","author":"Mudaliar","year":"2016","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1053\/j.ajkd.2020.03.019_bib31","first-page":"701","article-title":"A\u00a0more tubulocentric view of diabetic kidney disease","volume":"30","author":"Zeni","year":"2017","journal-title":"J\u00a0Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2020.03.019_bib32","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"issue":"4","key":"10.1053\/j.ajkd.2020.03.019_bib33","first-page":"3625","article-title":"Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1-receptor for advanced glycation end products-nuclear factor-\u03baB signaling pathway","volume":"18","author":"Yao","year":"2018","journal-title":"Mol Med Rep"},{"issue":"6","key":"10.1053\/j.ajkd.2020.03.019_bib34","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s00125-019-4839-8","article-title":"Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program","volume":"62","author":"Matthews","year":"2019","journal-title":"Diabetologia"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638620307137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638620307137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:29:39Z","timestamp":1759462179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638620307137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0272638620307137"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2020.03.019","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2020.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}